Characterization of the cytotoxic activities of novel analogues of the antitumor agent, lavendamycin

Molecular Cancer Therapeutics

Volumn 2, Issue 6, 2003, Pages 517-526

  Fang, Yanan ^a   Linardic, Corinne M ^a,b   Richardson, D Ashley ^a   Cai, Wen ^c   Behforouz, Mohammad ^c   Abraham, Robert T ^d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BALL STATE UNIVERSITY   (United States)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; HRAS PROTEIN, HUMAN; LAVENDAMYCIN; PROTEIN P21; PROTEIN P53; RUFOCROMOMYCIN;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CELL CYCLE; CELL CYCLE G2 PHASE; CHEMICAL MODEL; CHEMISTRY; FLOW CYTOMETRY; HUMAN; IMMUNOBLOTTING; MITOSIS; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; G2 PHASE; HUMANS; IMMUNOBLOTTING; MITOSIS; MODELS, CHEMICAL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); STREPTONIGRIN; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 1542439672     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Doyle, T. W., Balitz, D. M., Grulich, R. E., Nettleton, D. E., Gould, S. J., Tann, C., and Moews, A. E. Structure determination of lavendamycin, a new antitumor antibiotic from Streptomyces lavendulae. Tetrahedron Lett., 22: 4595-4598, 1981. (Pubitemid 12208560)
2. Balitz, D. M., Bush, J. A., Bradner, W. T., Doyle, T. W., O'Herron, F. A., and Nettleton, D. E. Isolation of lavendamycin, a new antibiotic from Streptomyces lavendulae. J. Antibiot. (Tokyo), 35: 259-265, 1982. (Pubitemid 12076462)
3. Abe, N., Nakakita, Y., Nakamura, T., Enoki, N., Uchida, H., Takeo, S., and Munekata, M. Novel cytocidal compounds, oxopropalines from Streptomyces sp. G324 producing lavendamycin. I. Taxonomy of the producing organism, fermentation, isolation and biological activities. J. Antibiot. (Tokyo), 46: 1672-1677, 1993. (Pubitemid 23355452)
4. Boger, D. L., Yasuda, M., Mitscher, L. A., Drake, S. D., Kitos, P. A., and Thompson, S. C. Streptonigrin and lavendamycin partial structures. Probes for the minimum, potent pharmacophore of streptonigrin, lavendamycin, and synthetic quinoline-5,8-diones. J. Med. Chem., 30: 1918-1928, 1987. (Pubitemid 18020928)
5. Behforouz, M., Haddad, J., Cai, W., Arnold, M. B., Mohammadi, F., Sousa, A. C., and Horn, M. A. Highly efficient and practical syntheses of lavendamycin methyl ester and related novel quinolindiones. J. Org. Chem., 61: 6552-6555, 1996. (Pubitemid 26328640)
6. Behforouz, M., and Merriman, R. L. Lavendamycin analogs and methods of making and using them. United States Patent 5, 525, 611, 6-11-1996.
7. Behforouz, M., Gu, Z., Cai, W., Horn, M. A., and Ahmadian, M. A highly concise synthesis of lavendamycin methyl ester. J. Org. Chem., 58: 7089-7091, 1993. (Pubitemid 24015774)
8. Monga, M., and Sausville, E. A. Developmental Therapeutics Program at the NCI: molecular target and drug discovery process. Leukemia (Baltimore), 16: 520-526, 2002. (Pubitemid 34449729)
9. Rubinstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst. (Bethesda), 82: 1113-1118, 1990. (Pubitemid 20213251)
10. Hollingshead, M., Plowman, J., Alley, M., Mayo, J., and Sausville, E. A. The hollow fiber assay. In: H. H. Fiebig and A. M. Burger (eds.), Relevance of Tumor Models for Anticancer Drug Development., pp. 109-120. Basel: Karger, 1999.
11. Sarkaria, J. N., Busby, E. C., Tibbetts, R. S., Roos, P., Taya, Y., Karnitz, L. M., and Abraham, R. T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res., 59: 4375-4382, 1999. (Pubitemid 29418757)
12. Theyer, G., Schirmbock, M., Thalhammer, T., Sherwood, E. R., Baumgartner, G., and Hamilton, G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J. Urol., 150: 1544-1547, 1993. (Pubitemid 24356225)
13. Huang, H., Cheville, J. C., Pan, Y., Roche, P. C., Schmidt, L. J., and Tindall, D. J. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem., 276: 38830-38836, 2001.
14. Chandar, N., Billig, B., McMaster, J., and Novak, J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br. J. Cancer, 65: 208-214, 1992.
15. Carroll, A. G., Voeller, H. J., Sugars, L., and Gelmann, E. P. p53 oncogene mutations in three human prostate cancer cell lines. Prostate, 23: 123-134, 1993. (Pubitemid 23289894)
16. Cai, Z., Capoulade, C., Moyret-Lalle, C., Amor-Gueret, M., Feunteun, J., Larsen, A. K., Paillerets, B. B., and Chouaib, S. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function. Oncogene, 15: 2817-2826, 1997. (Pubitemid 28004570)
17. Ljungman, M. Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. Neoplasia, 2: 208-225, 2000. (Pubitemid 30346077)
18. Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., and Ziv, Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (Wash. DC), 281: 1674-1677, 1998.
19. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (Wash. DC), 281: 1677-1679, 1998. (Pubitemid 28435584)
20. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev., 13: 152-157, 1999. (Pubitemid 29061945)
21. Shieh, S. Y., Ikeda, M., Taya, Y., and Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell, 91: 325-334, 1997. (Pubitemid 27467963)
22. Russell, K. J., Wiens, L. W., Demers, G. W., Galloway, D. A., Le, T., Rice, G. C., Bianco, J. A., Singer, J. W., and Groudine, M. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. Int. J. Radiat. Oncol. Biol. Phys., 36: 1099-1106, 1996.
23. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993. (Pubitemid 23346377)
24. Gurley, L. R., D'Anna, J. A., Barham, S. S., Deaven, L. L., and Tobey, R. A. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur. J. Biochem., 84: 1-15, 1978. (Pubitemid 8286682)
25. Raynal, P., and Pollard, H. B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim. Biophys. Acta, 1197: 63-93, 1994.
26. Wilson, W. L., Labra, C., and Barrist, E. Preliminary observation on the use of streptonigrin as an antitumor agent in human beings. Antibiot. Chemother., 11: 147-150, 1961.
27. Hackethal, C. A., Golbey, R. B., Tan, C. T. C., Karnofsky, D. A., and Burchenal, J. H. Clinical observations on the effects of streptonigrin in patients with neoplastic disease. Antibiot. Chemother., 11: 178-183, 1961.
28. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
29. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 15: 2177-2196, 2001. (Pubitemid 32843830)
30. Herlt, A. J., Rickards, R. W., and Wu, J. P. The structure of streptonigrone, and a comment on the biosynthesis of the streptonigrin antibiotics. J. Antibiot. (Tokyo), 38: 516-518, 1985. (Pubitemid 15112998)
31. Inouye, Y., Okada, H., Roy, S. K., Miyasaka, T., Hibino, S., Tanaka, N., and Nakamura, S. Biological properties of streptonigrin derivatives. I. Antimicrobial and cytocidal activities. J. Antibiot. (Tokyo), 38: 1429-1432, 1985. (Pubitemid 16206718)
32. Rao, K. V., and Beach, J. W. Streptonigrin and related compounds. 5. Synthesis and evaluation of some isoquinoline analogues. J. Med. Chem., 34: 1871-1879, 1991.
33. Bachur, N. R., Gordon, S. L., Gee, M. V., and Kon, H. NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc. Natl. Acad. Sci. USA, 76: 954-957, 1979. (Pubitemid 9130981)
34. Doroshow, J. H. Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones. Proc. Natl. Acad. Sci. USA, 83: 4514-4518, 1986. (Pubitemid 16057079)
35. Cone, R., Hasan, S. K., Lown, J. W., and Morgan, A. R. The mechanism of the degradation of DNA by streptonigrin. Can. J. Biochem., 54: 219-223, 1976.
36. Lown, J. W., Sim, S. K., and Chen, H. H. Hydroxyl radical production by free and DNA-bound aminoquinone antibiotics and its role in DNA degradation. Electron spin resonance detection of hydroxyl radicals by spin trapping. Can. J. Biochem., 56: 1042-1047, 1978. (Pubitemid 9081058)
37. 2 arrest after DNA damage. Science (Wash. DC), 282: 1497-1501, 1998.
38. 2/M checkpoints are induced by ionizing irradiation. Mol. Cell. Biol., 22: 1049-1059, 2002.
39. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Investig., 104: 263-269, 1999.
40. Reilly, H. C., and Sugiura, K. An antitumor spectrum of streptonigrin. Antibiot. Chemother., 11: 174-177, 1961.
41. Oleson, J. J., Calderella, L. A., Mjos, K. J., Reith, A. R., Thie, R. S., and Toplin, I. The effects of streptonigrin on experimental tumors. Antibiot. Chemother., 11: 158-164, 1961.
42. Paull, K. D., Shoemaker, R. H., Hodes, L., Monks, A., Scudiero, D. A., Rubinstein, L., Plowman, J., and Boyd, M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer Inst. (Bethesda), 81: 1088-1092, 1989. (Pubitemid 19175145)
43. Cohen, S. M., and Lippard, S. J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol., 67: 93-130, 2001. (Pubitemid 33804642)